Insmed Inc
NASDAQ:INSM

Watchlist Manager
Insmed Inc Logo
Insmed Inc
NASDAQ:INSM
Watchlist
Price: 176.95 USD 6.24% Market Closed
Market Cap: 37.7B USD

Gross Margin
Insmed Inc

76.5%
Current
77%
Average
63.1%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
76.5%
=
Gross Profit
342.2m
/
Revenue
447m

Gross Margin Across Competitors

No Stocks Found

Insmed Inc
Glance View

Insmed Inc., a biopharmaceutical company rooted in Bridgewater, New Jersey, emerged from the desire to tackle serious and rare diseases with potentially groundbreaking therapies. The company's journey is defined by its commitment to developing novel treatments for patients suffering from conditions often overlooked by mainstream pharmaceutical firms. At the heart of Insmed's operations lies its pursuit of treatments for rare pulmonary diseases, with its flagship product, ARIKAYCE, exemplifying their mission in action. Approved by the FDA for treating Mycobacterium avium complex (MAC) lung disease, ARIKAYCE represents a significant breakthrough, addressing a critical unmet medical need. By targeting specific patient populations with limited options, Insmed taps into niche markets where they face less competition and, simultaneously, a profound opportunity to make a meaningful impact on patient lives. The company's strategy revolves around leveraging innovative science to build a pipeline rich with potential treatments across various stages of clinical development. It focuses on expanding the use of ARIKAYCE, while also exploring new formulations and indications. Insmed channels resources into research and development, securing patent protections and establishing a robust global presence to ensure its therapies reach the patients who need them. Revenues are primarily generated through product sales, with ARIKAYCE as the cornerstone, alongside strategic partnerships and collaborations that allow for shared expertise and resources. This business model positions Insmed not only as a healthcare provider but as a key player in the biopharmaceutical industry, striving to transform lives by bringing forth meaningful medical innovations.

INSM Intrinsic Value
70.02 USD
Overvaluation 60%
Intrinsic Value
Price
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
76.5%
=
Gross Profit
342.2m
/
Revenue
447m
What is the Gross Margin of Insmed Inc?

Based on Insmed Inc's most recent financial statements, the company has Gross Margin of 76.5%.

Back to Top